IN2014MN01781A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01781A
IN2014MN01781A IN1781MUN2014A IN2014MN01781A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A IN 1781MUN2014 A IN1781MUN2014 A IN 1781MUN2014A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A
Authority
IN
India
Prior art keywords
cdim
binding proteins
cells
well
diagnostic assays
Prior art date
Application number
Inventor
Nelson N H Teng
Neelirna M Bhat
Marcia M Bieber
Bruce A Keyt
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of IN2014MN01781A publication Critical patent/IN2014MN01781A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present disclosure relates to Cell Death Inducing Molecule ('CDIM') binding proteins and pharmaceutical compositions thereof. Particularly the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells including neoplastic B cells as well as neoplastic cells that are not of B cell origin that express CDIM like antigens. In addition the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.
IN1781MUN2014 2012-02-08 2013-02-08 IN2014MN01781A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261633330P 2012-02-08 2012-02-08
PCT/US2013/025430 WO2013120012A2 (en) 2012-02-08 2013-02-08 Cdim binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
IN2014MN01781A true IN2014MN01781A (en) 2015-07-03

Family

ID=48045015

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1781MUN2014 IN2014MN01781A (en) 2012-02-08 2013-02-08

Country Status (15)

Country Link
US (1) US9409976B2 (en)
EP (1) EP2812356B1 (en)
JP (1) JP6335796B2 (en)
KR (1) KR102102111B1 (en)
CN (1) CN104254544B (en)
AU (1) AU2013200903B2 (en)
BR (1) BR112014019459B1 (en)
CA (1) CA2863714C (en)
DK (1) DK2812356T3 (en)
ES (1) ES2735289T3 (en)
HK (1) HK1205136A1 (en)
IN (1) IN2014MN01781A (en)
MX (1) MX363819B (en)
TW (1) TWI606064B (en)
WO (1) WO2013120012A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
EP3083678B1 (en) * 2013-12-17 2019-04-03 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
CN105992772A (en) 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA multi-specific binding molecules
SG11201608194VA (en) 2014-04-03 2016-10-28 Igm Biosciences Inc Modified j-chain
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
KR20230130148A (en) * 2015-03-04 2023-09-11 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 binding molecules and uses thereof
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP6811723B2 (en) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent human immunodeficiency virus antigen-binding molecule and its usage
ES2819870T3 (en) 2015-09-30 2021-04-19 Igm Biosciences Inc Modified J-chain binding molecules
US10618978B2 (en) 2015-09-30 2020-04-14 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CN109641965A (en) * 2016-08-15 2019-04-16 诺华股份有限公司 Use the scheme and method of difficult to understand treatment multiple sclerosis
EP3579848A4 (en) 2017-02-08 2021-03-03 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
AU2018220736A1 (en) 2017-02-20 2019-09-05 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN112368012A (en) 2018-02-08 2021-02-12 蜻蜓疗法股份有限公司 Antibody variable domains targeting NKG2D receptor
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
EP3880714A4 (en) * 2018-11-16 2022-07-20 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
CN114181318B (en) * 2021-11-08 2023-08-01 四川大学 Recombinant adeno-associated virus for tissue-specific expression of IDUA fusion protein penetrating blood brain barrier and application thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3920358A1 (en) * 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6962979B1 (en) 1995-03-14 2005-11-08 Cohesion Technologies, Inc. Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
IL148718A0 (en) 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1485075A4 (en) * 2002-02-20 2006-04-26 Dyax Corp Mhc-peptide complex binding ligands
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US20120237441A9 (en) * 2003-11-05 2012-09-20 Bhat Neelima M Enhanced b cell cytotoxicity of cdim binding antibody
WO2005044998A2 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
EP1814913B1 (en) * 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antibody induced cell membrane wounding
EP2336174B8 (en) * 2005-03-14 2015-09-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Human monoclonal antibodies against Hendra and Nipah viruses
AU2006292132A1 (en) * 2005-09-19 2007-03-29 Palingen, Inc. Treatment of B cell diseases using anti-germline antibody binding agents
PA8775101A1 (en) * 2007-04-02 2008-11-19 Pfizer ANTI-IGE ANTIBODIES

Also Published As

Publication number Publication date
JP2015511817A (en) 2015-04-23
BR112014019459A2 (en) 2017-06-27
ES2735289T3 (en) 2019-12-17
MX363819B (en) 2019-04-03
CA2863714C (en) 2022-07-05
CN104254544A (en) 2014-12-31
BR112014019459B1 (en) 2023-04-18
HK1205136A1 (en) 2015-12-11
EP2812356A2 (en) 2014-12-17
BR112014019459A8 (en) 2023-01-10
EP2812356B1 (en) 2019-03-27
AU2013200903A1 (en) 2013-08-22
DK2812356T3 (en) 2019-07-08
KR20150001728A (en) 2015-01-06
CN104254544B (en) 2017-04-26
WO2013120012A3 (en) 2013-11-07
TW201345921A (en) 2013-11-16
US9409976B2 (en) 2016-08-09
WO2013120012A2 (en) 2013-08-15
KR102102111B1 (en) 2020-04-20
CA2863714A1 (en) 2013-08-15
US20140044739A1 (en) 2014-02-13
AU2013200903B2 (en) 2015-05-14
JP6335796B2 (en) 2018-06-06
MX2014009628A (en) 2015-03-19
TWI606064B (en) 2017-11-21

Similar Documents

Publication Publication Date Title
IN2014MN01781A (en)
PH12019500441A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500639A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
MX349096B (en) Anti-pd-l1 antibodies and uses thereof.
TN2015000177A1 (en) Anti-ceacam5 antibodies and uses thereof
MX2017014082A (en) Proteins specific for cd137.
MX2014008963A (en) Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine.
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
UA118332C2 (en) Cs27l antigen binding proteins
BR112014029099A2 (en) anti-egfr antibodies and their use to inhibit or attenuate tumor growth, as well as a pharmaceutical composition comprising
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
IN2014CN03936A (en)
BR112013019975A2 (en) "Antigen binding proteins, pharmaceutical composition, use of an antigen binding protein, method for treating a patient and method for preparing an antigen binding protein, nucleic acid, vector and host cell"
MX2013011921A (en) Aryl-or heteroaryl-substituted benzene compounds.
MY156286A (en) Human il-23 antigen binding proteins
GB201201314D0 (en) Composition
IN2014CN04645A (en)
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
NZ701370A (en) Il-6 binding molecules
EA201370155A1 (en) COMPOSITION AND METHOD OF TREATMENT OF CANCER
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
BR112012014345A2 (en) tmem22 peptides and vaccines including the same
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
TN2013000265A1 (en) Anti-cd38 antibodies